Comparing doctor visits with nurse remote checks after rare tumor treatment
Compares in-person doctor follow-up with remote nurse follow-up in adults with rare tumors.
Plain-language title generated from the registry record
Registry title: Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Key facts
- Where
- Amiens, Caen, and Lille, FranceSee the 3 sites
- Phase
- Phase 2
Where in France
- CHU AmiensAmiens, FranceNot yet recruiting
- Centre François BaclesseCaen, FranceNot yet recruiting
- Centre Oscar LambretLille, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Oscar Lambret
- Trial code
- NCT05500391
- Record updated
- 18 March 2026
- Original description
This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan, established for each patient according to national guidelines, when the surveillance is conducted in person by a hospital-based physician (control arm) or remotely by a trained nurse (experimental arm).Read full original descriptionShow less
Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring
This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan, established for each patient according to national guidelines, when the surveillance is conducted in person by a hospital-based physician (control arm) or remotely by a trained nurse (experimental arm).
Inclusion: Positive diagnosis (anatomopathology) of tumor within 12 months; Patient 18 years of age or older; Patient with one of the following conditions:; Desmoid fibromatosis of the abdominal wall operated on or under active surveillance; Stage I testicular seminoma (whether or not treated with carboplatin AUC7); Stage I non-seminomatous germ cell tumor (with or without adjuvant BEP chemotherapy); Operated GIST with low risk of relapse; Rare gynecological tumors (sex cord and stromal tumors; germ cell tumors of the ovary, clear cell adenocarcinoma, mucinous adenocarcinoma of the ovary, borderline tumors, small cell carcinoma, ovarian and uterine carcinosarcoma, low grade serous tumors), operated; Low-grade glioma, operated; Low-grade neuroendocrine tumor, treated by surgery alone; Patient who has given consent to participate in the study.
Exclusion: Contraindication to imaging tests required for the surveillance plan; No telephone; Patient under guardianship or curatorship.